Pyrrolidines
Medchemexpress LLC E/Z-HA155 5mg | 1229652-22-5 | 5 MG
(E/Z)-HA155 is a small-molecule autotaxin (ATX) type I inhibitor used in preclinical research to study cancer, fibrotic diseases, inflammation, pain, and angiogenesis. Supplied as a high-purity powder with recommended cold storage, it is available in multiple pack sizes and as a DMSO solution for biological assays.
- High purity: 99.3% (rounded from manufacturer specification).
- Molecular weight approximately 463.29 g·mol⁻¹.
- Chemical formula C24H19BFNO5S.
- Recommended storage: powder at -20°C; solutions at -80°C for long-term storage.
- Available in small research quantities and as a 10 mM solution in DMSO for assay use.
- Supplied with a certificate of analysis and safety data sheet for quality and handling information.
Medchemexpress LLC E/Z-HA155 50mg | 1229652-22-5 | 50 MG
(E/Z)-HA155 is a boronic acid small-molecule autotaxin (ATX) type I inhibitor supplied as an E/Z isomer mixture for preclinical research. It is used to study cancer, fibrotic diseases, inflammation, pain, and angiogenesis. Supplied as a high-purity solid suitable for biochemical and cell-based assays; recommended storage is powder at -20°C.
- Boronic acid small molecule inhibitor of autotaxin.
- Used in research on cancer, fibrosis, inflammation, pain, and angiogenesis.
- Molecular formula C24H19BFNO5S.
- Molecular weight 463.29 g/mol.
- Purity approximately 99.3%.
- Appearance: solid, off-white to light yellow.
- Recommended storage: powder at -20°C; in solvent keep at -80°C for longer-term, -20°C short-term.
Medchemexpress LLC E/Z-HA155 25mg | 1229652-22-5 | 463.29 | C24H19BFNO5S | 25 MG
A potent autotaxin (ATX) type I inhibitor for laboratory research, (E/Z)-HA155 is used to study cancer, fibrotic disease, inflammation, pain, and angiogenesis. The product is supplied as a high-purity solid and includes supporting structural and stability data for experimental use.
- Potent autotaxin (ATX) type I inhibitor for mechanistic and pharmacology studies.
- High purity suitable for analytical and biological assays.
- Supplied as a solid 25 mg quantity for small-scale experiments.
- Stable when stored as a powder at -20°C for extended periods.
- Structural identifiers and formula provided for computational and analytical workflows.
Medchemexpress LLC E/Z-HA155 10mg | 1229652-22-5 | 463.29 g/mol | C24H19BFNO5S | 10 MG
(E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor supplied for laboratory research use. It is used to support studies into cancer, fibrotic diseases, inflammation, pain, and angiogenesis. For research use only; not for human or clinical application.
- Potent autotaxin type I inhibition for biochemical assays.
- Applicable to cancer, fibrosis, inflammation, pain, and angiogenesis research.
- High purity (99.26%) suitable for cellular and biochemical experiments.
- Supplied as a small-scale powder for dose optimization and pilot studies.
- Stored and handled per standard laboratory safety procedures for research reagents.
Medchemexpress LLC E/Z-HA155 100mg | 1229652-22-5 | 463.29 g/mol | C24H19BFNO5S | 100 MG
(E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor used as a research reagent in studies of cancer, fibrotic diseases, inflammation, pain, and angiogenesis. The compound is provided as solid and as DMSO solutions, has high reported purity, and specific storage conditions are supplied for long-term stability.
- Potent autotaxin (ATX) type I inhibitor for biochemical and cellular assays.
- High reported purity: 99.26%.
- Available in multiple quantities including 100 MG solid and 10 mM solution in DMSO.
- Chemical formula C24H19BFNO5S and molecular weight 463.29 g/mol for formulation reference.
- Storage recommendations: powder at -20°C for up to 3 years; in solvent at -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC E/Z-HA155 1mg | 1229652-22-5 | 463.29 g·mol-1 | C24H19BFNO5S | 1 MG
(E/Z)-HA155 is a boronic acid-based autotaxin (ATX) type I inhibitor used in preclinical research. It is reported to inhibit ATX with high potency (IC50 ≈ 5.7 nM) and is used to study cancer, fibrotic diseases, inflammation, pain, and angiogenesis.
- Potent autotaxin (ATX) type I inhibitor (IC50 ≈ 5.7 nM).
- High purity: 99.26%.
- Available in multiple lab-scale pack sizes, including 1 mg vials and DMSO solution.
- Molecular formula C24H19BFNO5S; molecular weight 463.29 g·mol-1.
- Supplied as an E/Z isomer mixture suitable for biochemical and cell-based assays.
Medchemexpress LLC Benzenesulfonamide, 4-amino-N-(5-chloro-2-quinoxalinyl) | 97919-22-7 | 99.1% | 334.78 g/mol | C14H11ClN4O2S | 100 MG
Chloroquinoxaline sulfonamide (CAS 97919-22-7) is a research reagent that acts as a topoisomerase II α/β poison with reported antiparasitic and antitumor activity. It is supplied as a solid for laboratory use and is soluble in DMSO.
- Functions as a topoisomerase II alpha/beta poison.
- Exhibits antiparasitic and antitumor activity in research studies.
- Molecular formula C14H11ClN4O2S; molecular weight 334.78 g/mol.
- Soluble in DMSO: 125 mg/mL (approx. 373.38 mM).
- Recommended storage: powder at -20°C (up to 3 years) or 4°C (up to 2 years).
- Typical purity provided: 99.06% by HPLC.
Medchemexpress LLC Rac-WAY-161503 hydrochloride | 276695-22-8 | MFCD06411596 | 99.5% | 308.59 g/mol | C11H12Cl3N3O | 5 MG
(Rac)-WAY-161503 hydrochloride is a racemic research compound that acts as a potent and selective 5-HT2C receptor agonist for neuroscience studies. Supplied as a high-purity solid, it is intended for use in in vitro and in vivo laboratory research.
- Potent, selective 5-HT2C receptor agonist (Ki = 4 nM; EC50 = 12 nM).
- High purity (99.5%).
- Molecular weight 308.59 g/mol.
- White to off-white solid physical form.
- CAS registry number 276695-22-8.
- Store powder at -20°C for long-term stability.
- Provided in small milligram quantities suitable for research (5 mg typical).
eMolecules AstaTech / 22-DIMETHYL-3-OXO-PYRROLIDINE-1-CARBOXYLIC ACID ETHYL ESTER / 1g / 112526618 / 60570 / 97.000 / 106556-66-5 / MFCD09835297 / 185.223 / C9H15NO3
AstaTech / 22-DIMETHYL-3-OXO-PYRROLIDINE-1-CARBOXYLIC ACID ETHYL ESTER / 1g / 112526618 / 60570 / 97.000 / 106556-66-5 / MFCD09835297 / 185.223 / C9H15NO3
Sigma Aldrich 1-Cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
MilliporeSigma Sigma Organics products encompass a wide range of quality reagents, solvents, catalysts, and building blocks for organic synthesis. From benchtop discovery to process development and scale-up, Sigma Organics solutions are built to meet the needs of synthetic chemists.
Cayman Chemical 9 Z 11 E 13 EOctadecatrienoic
A fatty acid agonist of PPARγ; activates PPARγ transcriptional activity in a reporter assay using RAW 264.7 cells at 10 µM; an inhibitor of DNA polymerase α, -β, -γ, -Δ, and -ε (IC50s = 10.7, 13.4, 10.6, 14, and 22 µM, respectively); an inhibitor of topoisomerase I and -II (IC50s = 20 and 5 µM, respectively); reduces the viability of, and induces apoptosis in, MCF-7 breast cancer cells in a concentration-dependent manner; induces ferroptosis in MDA-MB-231 breast cancer cells in an ACSL1-dependent manner; reduces clinical signs of disease in a model of DSS-induced IBD in PPARγ-expressing, but not PPARγ-knockout, mice
Cayman Chemical 9 Z 11 E 13 EOctadecatrienoic
A fatty acid agonist of PPARγ; activates PPARγ transcriptional activity in a reporter assay using RAW 264.7 cells at 10 µM; an inhibitor of DNA polymerase α, -β, -γ, -Δ, and -ε (IC50s = 10.7, 13.4, 10.6, 14, and 22 µM, respectively); an inhibitor of topoisomerase I and -II (IC50s = 20 and 5 µM, respectively); reduces the viability of, and induces apoptosis in, MCF-7 breast cancer cells in a concentration-dependent manner; induces ferroptosis in MDA-MB-231 breast cancer cells in an ACSL1-dependent manner; reduces clinical signs of disease in a model of DSS-induced IBD in PPARγ-expressing, but not PPARγ-knockout, mice
Cayman Chemical 9 Z 11 E 13 EOctadecatrienoic
A fatty acid agonist of PPARγ; activates PPARγ transcriptional activity in a reporter assay using RAW 264.7 cells at 10 µM; an inhibitor of DNA polymerase α, -β, -γ, -Δ, and -ε (IC50s = 10.7, 13.4, 10.6, 14, and 22 µM, respectively); an inhibitor of topoisomerase I and -II (IC50s = 20 and 5 µM, respectively); reduces the viability of, and induces apoptosis in, MCF-7 breast cancer cells in a concentration-dependent manner; induces ferroptosis in MDA-MB-231 breast cancer cells in an ACSL1-dependent manner; reduces clinical signs of disease in a model of DSS-induced IBD in PPARγ-expressing, but not PPARγ-knockout, mice